IP Library › Patent Application 17864025
Patent Application
App. No. 17/864,025

BIOSENSOR FOR DETECTION OF SARS-COV-2 SPIKE GLYCOPROTEIN AND RELATED METHODS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/864,025
Abstract

An example biosensor includes a substrate, a graphene layer disposed on the substrate, and a binding site bonded to the graphene. The binding site includes an antibody configured to bind a SARS-CoV- 2 spike glycoprotein.

Claims (34)

1 . A biosensor, comprising:

a substrate;

a graphene layer disposed on the substrate; and

a binding site bonded to the graphene layer, the binding site including an antibody configured to bind a SARS-CoV-2 spike glycoprotein.

2 . The biosensor of claim 1 , further comprising:

a first subsensor; and

a second subsensor spaced apart from the first subsensor;

wherein the first subsensor includes a first binding site, and the second subsensor includes a second binding site that is different from the first binding site.

3 . The biosensor of claim 2 , wherein:

the first subsensor includes an antibody configured to bind a SARS-CoV-2 spike protein of a first variant;

the second subsensor includes an antibody configured to bind a SARS-CoV-2 spike protein of a second variant; and

the first variant is different from the second variant.

4 . The biosensor of claim 3 , wherein:

the first variant includes a SARS-CoV-2 spike protein from a natural infection; and

the second variant includes a SARS-CoV-2 spike protein from a vaccine.

5 . The biosensor of claim 1 , wherein the biosensor is configured to detect the SARS-CoV-2 spike protein in at least one of a saliva sample or a blood sample.

6 . The biosensor of claim 1 , wherein the biosensor is configured to determine a quantity of spike glycoprotein.

7 . The biosensor of claim 1 , wherein the antibody is polyclonal.

8 . The biosensor of claim 1 , wherein the antibody comprises at least one of a single-chain variable fragment (scFV) or an antigen-binding fragment (Fab).

9 . The biosensor of claim 1 , wherein the antibody comprises IML anti-11 DehydroThromboxane.

10 . The biosensor of claim 1 , wherein the biosensor comprises a Raman spectrometer.

11 . The biosensor of claim 1 , wherein the biosensor comprises at least one of an impedance-based detector or a field effect transistor (FET).

12 . The biosensor of claim 1 , wherein the biosensor comprises a multi-analyte array.

13 . A method to detect a spike glycoprotein, comprising:

forming a biosensor by depositing at least one graphene layer on a substrate, wherein the at least one graphene layer includes one or more binding sites;

forming an electrical contact on the at least one graphene layer or the substrate; and

attaching an antibody to the at least one graphene layer, wherein the antibody is configured to bind a target from a sample.

14 . The method of claim 13 , wherein the target comprises a SARS-CoV-2 spike protein.

15 . The method of claim 13 , wherein the sample comprises at least one of saliva or blood.

16 . The method of claim 13 , further comprising performing Raman spectroscopy on the sample.

17 . The method of claim 13 , wherein the one or more antibodies is polyclonal.

18 . The method of claim 13 , wherein the one or more antibodies comprises a recombinant antibody.

19 . The method of claim 13 , wherein the one or more antibodies comprise at least one of a single-chain variable fragment (scFV) or an antigen-binding fragment (Fab).

20 . The method of claim 13 , wherein the one or more antibodies is multispecific.